An interventional study of Digital Home-Based Prehabilitation and Standard Perioperative Care in Non-Small Cell Lung Cancer (NSCLC), Rehabilitation and Thoracic Surgery, sponsored by West China Hospital. Recruiting at 1 site in China. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by West China Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital — 14 open to participants now, 14 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · West China Hospital.
Among the 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 9 that started in 2026, is one of 6 with no phase, reaches primary completion later than 8 of the 13 other live ones, and was the 14th registered.
7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →14 of the 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital are open now, in 1 country. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 18–80
West China Hospital · Sites in China
Ages 18–80
West China Hospital · Sites in China
Ages 18+
West China Hospital · Sites in China
Ages 60–90
West China Hospital · Sites in China
Ages 18–85
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 65 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 1 · Phase 4 1
First in 2017; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 196 is above the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 82 across the 15 interventional studies, 200 across the 3 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
West China Hospital is the lead sponsor of 503 studies on the registry; 247 are open to participants now.
2 of the studies in Carcinoma, Non-Small-Cell Lung by West China Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07310056West China HospitalThe Construction and Clinical Application of an Integrated Perioperative Management System for Lung Cancer Based on Wearable Devices and Intelligent Platforms | 2026-12-01 |
| NCT07106827West China HospitalA Study of GV20-0251 in Advanced or Refractory Solid Tumors | 2027-06-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Carcinoma, Non-Small-Cell Lung by West China Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled trial evaluates the efficacy and safety of a home-based prehabilitation program using wireless wearable monitoring devices in older patients (aged 65-85 years) with non-small cell lung cancer scheduled for curative lung resection. Participants are randomized 1:1 to either the intervention group, receiving a personalized exercise regimen (aerobic, resistance, and inspiratory muscle training) with continuous remote monitoring of steps, heart rate, and SpO₂ from 2-4 weeks preoperatively through 90 days postoperatively, or the control group receiving standard perioperative care. The primary endpoint is the between-group difference in FEV₁% predicted at 90 days post-surgery, adjusted for baseline. Secondary endpoints include functional capacity (6-minute walk distance), daily physical activity, hypoxemic burden (time with SpO₂\<90%, nocturnal oxygen desaturation index), patient-reported outcomes (EORTC QLQ-C30/LC13, mMRC), postoperative complications, readmission rates, days alive and at home, and safety outcomes. The target sample size is 198 participants enrolled at West China Hospital of Sichuan University. Anticipated risks include exercise-related musculoskeletal strain, fatigue, and transient cardiopulmonary symptoms, as well as mild skin reactions from devices, all managed through individualized exercise prescriptions, remote safety thresholds, and a graded response protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a wireless wearable monitoring system (smartwatch/ring and fingertip pulse oximeter) to continuously track steps, moderate-to-vigorous physical activity, heart rate, SpO₂, and sleep. A personalized home-based exercise program is prescribed, including moderate-intensity aerobic exercise (≥5 days/week, 30-45 min/session), inspiratory muscle training (twice daily), and functional/chest expansion exercises, starting 2-4 weeks before surgery and continuing until 90 days postoperatively. Remote monitoring with automated safety alerts (e.g., SpO₂\<90% for ≥5 min, step count drop ≥40%) triggers a graded response protocol. Participants also receive nutritional guidance, smoking cessation advice, and complication education. All interventions are delivered via a digital health platform with regular remote follow-up.
Behavioral: Digital Home-Based Prehabilitation
Participants receive the institution's standard enhanced recovery after surgery (ERAS) pathway, including routine preoperative education, postoperative physical therapy (chest physiotherapy, early mobilization), and standard nursing care. They do not receive the wearable monitoring devices, the structured remote exercise prescription, or the continuous digital supervision. The frequency and content of follow-up visits are identical to those of the intervention group for outcome assessment purposes, but no programmatic home prehabilitation or remote monitoring is provided.
Behavioral: Standard Perioperative Care
A home-based multimodal prehabilitation and rehabilitation program delivered via a digital health platform, supported by wireless wearable monitoring devices (smartwatch/ring and fingertip pulse oximeter). The intervention includes: (1) moderate-intensity aerobic exercise (≥5 days/week, 30-45 min/session, Borg scale 3-4), (2) inspiratory muscle training (twice daily), (3) functional and chest expansion exercises, and (4) nutritional guidance, smoking cessation advice, and complication education. The program starts 2-4 weeks preoperatively and continues through 90 days post-surgery. Continuous remote monitoring of steps, heart rate, SpO₂, and activity levels with automated safety alerts (e.g., SpO₂\<90% for ≥5 min, step drop ≥40%) triggers a graded clinical response. Participants receive regular remote follow-up and individualized exercise adjustments based on real-time data.
Participants receive the institution's standard enhanced recovery after surgery (ERAS) pathway, including routine preoperative education, postoperative chest physiotherapy, early mobilization guidance, and standard nursing care. No wearable monitoring devices, structured remote exercise prescriptions, digital health platform, or continuous remote supervision are provided. Follow-up visits are scheduled at the same time points as the intervention group for outcome assessment, but no programmatic home-based prehabilitation or tele-monitoring is delivered.
FEV₁% Predicted at 90 Days Post-Surgery
Forced expiratory volume in 1 second as a percentage of the predicted value, measured by spirometry according to ATS/ERS standards. The measurement is taken at the 90-day (±14 days) follow-up visit. The primary analysis compares the adjusted between-grou
Time frame: 90 days after surgery (±14 days)
Change From Baseline in FVC Percent Predicted
Forced vital capacity measured by spirometry according to ATS/ERS standards and expressed as a percentage of the predicted value. Change from the preoperative baseline value will be determined at 30 and 90 days after surgery.
Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days
Change From Baseline in FEV1/FVC Ratio
The ratio of forced expiratory volume in 1 second to forced vital capacity, measured by spirometry according to ATS/ERS standards. Change from the preoperative baseline value will be determined at 30 and 90 days after surgery.
Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days
Change From Baseline in 6-Minute Walk Distance
Distance walked during a 6-minute walk test performed on a flat, marked course according to ATS guidelines. Change from the preoperative baseline distance will be determined at 30 and 90 days after surgery.
Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days
Change in Borg Dyspnea Score During the 6-Minute Walk Test
Borg dyspnea scores will be recorded immediately before and immediately after each 6-minute walk test. The outcome is calculated as the post-test score minus the pre-test score.
Time frame: Baseline, 30 days after surgery with an allowable window of ±7 days, and 90 days after surgery with an allowable window of ±14 days
Mean Daily Step Count
The mean number of steps per day recorded by the wearable device. For the intervention group, step count will be recorded throughout the intervention period. For the control group, step count will be recorded during protocol-specified 7-day assessment periods. Daily values will be averaged across valid wear days, defined as days with at least 10 hours of wear time.
Time frame: Baseline through 90 days after surgery, summarized separately for postoperative days 0-30 and 31-90
Mean Daily Moderate-to-Vigorous Physical Activity
The mean duration of moderate-to-vigorous physical activity recorded by the wearable device. For the intervention group, activity will be recorded throughout the intervention period. For the control group, activity will be recorded during protocol-specified 7-day assessment periods. Values will be averaged across valid wear days, defined as days with at least 10 hours of wear time.
Time frame: Baseline through 90 days after surgery, summarized separately for postoperative days 0-30 and 31-90
Percentage of Monitoring Time With SpO2 Below 90%
The percentage of valid pulse-oximetry monitoring time during which peripheral oxygen saturation is below 90%, calculated from continuous or minute-level SpO2 recordings.
Time frame: Baseline through 90 days after surgery, summarized separately for postoperative days 0-30 and 31-90
Nocturnal Oxygen Desaturation Index
The mean number of nocturnal oxygen desaturation events per hour of valid overnight recording. An oxygen desaturation event is defined as a decrease in SpO2 of at least 3% from the preceding baseline level.
Time frame: Baseline through 90 days after surgery, summarized separately for postoperative days 0-30 and 31-90
Change From Baseline in EORTC QLQ-C30 Score
Health-related quality of life assessed using the EORTC QLQ-C30 Global Health Status/Quality of Life scale. Scores are transformed to a 0-100 scale according to the EORTC scoring manual, with higher scores indicating better global health status and quality of life. Change from the preoperative baseline score will be determined at 30 and 90 days after surgery.
Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days
Change From Baseline in EORTC QLQ-LC13 Score
Lung cancer-related symptoms assessed using the prespecified EORTC QLQ-LC13 scale or item. Scores will be calculated according to the EORTC scoring manual and transformed to a 0-100 scale. Change from the preoperative baseline score will be determined at 30 and 90 days after surgery. The direction of a higher score should be stated for the selected scale or item.
Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days
Change From Baseline in mMRC Dyspnea Scale Score
Dyspnea assessed using the modified Medical Research Council scale, ranging from 0 to 4, with higher scores indicating greater dyspnea-related functional limitation. Change from the preoperative baseline score will be determined at 30 and 90 days after surgery.
Time frame: Baseline to 30 days after surgery, with an allowable window of ±7 days, and baseline to 90 days after surgery, with an allowable window of ±14 days
Incidence of All-Cause Hospital Readmission Within 90 Days
Percentage of participants who have at least one unplanned hospital readmission for any cause during the first 90 days after surgery.
Time frame: Within 90 days after surgery
Incidence of Emergency Department Visits Within 90 Days
Percentage of participants who have at least one emergency department visit for any cause during the first 90 days after surgery.
Time frame: Within 90 days after surgery
Incidence of Postoperative Pulmonary Complications Within 90 Days
Percentage of participants who experience at least one postoperative pulmonary complication meeting the protocol-specified EPCO or CHEST criteria. Pulmonary complications include pneumonia, respiratory failure or re-intubation, atelectasis requiring intervention, acute respiratory distress syndrome, pleural effusion requiring drainage, bronchospasm requiring treatment, or pulmonary embolism. Each participant will be counted once regardless of the number of complications experienced.
Time frame: Within 90 days after surgery
Days Alive and at Home During the First 90 Days After Surgery
Number of days during the first 90 postoperative days that the participant is alive and not admitted to a hospital, rehabilitation facility, or other inpatient institutional care facility. The value is calculated as 90 minus the total number of days spent in hospital or institutional care. Participants who die within 90 days after surgery will be assigned a value of zero days.
Time frame: Within 90 days after surgery
Incidence of Adverse Events
Percentage of participants who experience at least one adverse event after providing informed consent. Adverse events will be identified and graded according to CTCAE version 5.0. Events of special interest include exercise-related, wearable-device-related, and oxygen-related adverse events. Each participant will be counted once regardless of the number of adverse events experienced.
Time frame: From signing informed consent through 90 days after surgery
Incidence of Serious Adverse Events
Percentage of participants who experience at least one serious adverse event after providing informed consent. Serious adverse events will be classified and graded according to the protocol and CTCAE version 5.0. Each participant will be counted once regardless of the number of serious adverse events experienced.
Time frame: From signing informed consent through 90 days after surgery
Wearable-Device Adherence Rate
Percentage of observed days on which the wearable device is worn for at least 12 hours. The numerator is the number of days meeting the required wear-time threshold, and the denominator is the total number of expected observation days.
Time frame: From baseline through 90 days after surgery
Exercise Prescription Completion Rate
Percentage of prescribed exercise sessions completed by participants in the intervention group. The numerator is the number of completed prescribed sessions, and the denominator is the total number of prescribed sessions during the intervention period.
Time frame: From baseline through 90 days after surgery
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jul 2028, 22 months later.
Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 22 months is below that.
Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →